{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:56:54Z","timestamp":1792803414482,"version":"4.5.0"},"reference-count":224,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012725","name":"Tecnol\u00f3gico Nacional de M\u00e9xico","doi-asserted-by":"crossref","award":["21837.25-P"],"award-info":[{"award-number":["21837.25-P"]}],"id":[{"id":"10.13039\/100012725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Camptothecin (CPT) is a natural alkaloid with potent antiproliferative activity, mediated by the inhibition of Topoisomerase I (Topo I), an essential enzyme for deoxyribonucleic acid (DNA) replication. However, its clinical application has been limited by low solubility and the instability of the lactone ring under physiological conditions, both of which decrease its efficacy. Semi-synthetic analogs such as irinotecan (CPT-11) and topotecan (TPT) have been developed and approved for the treatment of various types of cancer; however, challenges related to drug resistance and side effects continue to arise. Therefore, nanomedicine and nanoparticle-based delivery systems, including nanoemulsions, liposomes, and antibody\u2013drug conjugates (ADCs), emerge as promising strategies to improve the stability, bioavailability, and effectiveness of CPT, despite significant challenges such as scalability, pharmacokinetic variability, and regulatory requirements. This review discusses recent advances in CPT, its analogs, and these delivery platforms, highlighting its potential to optimize cancer therapy and reduce toxicity while outlining translational challenges such as scalability, pharmacokinetic variability, and regulatory requirements.<\/jats:p>","DOI":"10.3390\/pharmaceutics17111414","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:47:58Z","timestamp":1762177678000},"page":"1414","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions"],"prefix":"10.3390","volume":"17","author":[{"given":"Heber Uriel","family":"P\u00e9rez-Ortega","sequence":"first","affiliation":[{"name":"Divisi\u00f3n de Estudios de Posgrado e Investigaci\u00f3n (DEPI), Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Celaya (ITC), Celaya 38010, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9038-6749","authenticated-orcid":false,"given":"Rub\u00e9n Ricardo","family":"C\u00f3rdova-Esp\u00edritu","sequence":"additional","affiliation":[{"name":"Departamento de Ingenier\u00eda Bioqu\u00edmica y Ambiental, Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Celaya (ITC), Celaya 38010, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Cano-Serrano","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Estudios de Posgrado e Investigaci\u00f3n (DEPI), Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Celaya (ITC), Celaya 38010, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Roque (ITR), Celaya 38110, Guanajuato, Mexico"},{"name":"Programa de Ingenier\u00eda en Biotecnolog\u00eda, Campus Celaya-Salvatierra, Universidad de Guanajuato, Mutualismo #303, Col. La Suiza, Celaya 36060, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-4172","authenticated-orcid":false,"given":"Micael Gerardo","family":"Bravo-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Departamento de Ingenier\u00eda Bioqu\u00edmica y Ambiental, Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Celaya (ITC), Celaya 38010, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-9751","authenticated-orcid":false,"given":"Ma. del Carmen","family":"Orozco-Mosqueda","sequence":"additional","affiliation":[{"name":"Departamento de Ingenier\u00eda Bioqu\u00edmica y Ambiental, Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Celaya (ITC), Celaya 38010, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1084-5520","authenticated-orcid":false,"given":"Hugo","family":"Jim\u00e9nez-Islas","sequence":"additional","affiliation":[{"name":"Departamento de Ingenier\u00eda Bioqu\u00edmica y Ambiental, Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Celaya (ITC), Celaya 38010, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-6928","authenticated-orcid":false,"given":"Gabriel","family":"Luna-B\u00e1rcenas","sequence":"additional","affiliation":[{"name":"Tecnol\u00f3gico de Monterrey, Instituto de Materiales Avanzados para una Manufactura Sostenible, Epigmenio Gonz\u00e1lez 500 Fracc. San Pablo, Quer\u00e9taro 76130, Quer\u00e9taro, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0511","authenticated-orcid":false,"given":"Francisco","family":"Villase\u00f1or-Ortega","sequence":"additional","affiliation":[{"name":"Departamento de Ingenier\u00eda Bioqu\u00edmica y Ambiental, Tecnol\u00f3gico Nacional de M\u00e9xico (TecNM), Instituto Tecnol\u00f3gico de Celaya (ITC), Celaya 38010, Guanajuato, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref_1","first-page":"74","article-title":"Alimentaci\u00f3n y estilo de vida en la prevenci\u00f3n del c\u00e1ncer","volume":"39","year":"2022","journal-title":"Nutr. Hosp."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Singla, R.K., and Bishayee, A. (2025). Anticancer drug discovery based on natural products: From computational approaches to clinical studies. Cancers, 17.","DOI":"10.3390\/cancers17152507"},{"key":"ref_4","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"113639","DOI":"10.1016\/j.ejmech.2021.113639","article-title":"Camptothecin\u2019s journey from discovery to WHO Essential Medicine: Fifty years of promise","volume":"223","author":"Khaiwa","year":"2021","journal-title":"Eur J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yu, L., Jin, Y., Song, M., Zhao, Y., and Zhang, H. (2022). When natural compounds meet nanotechnology: Nature-inspired nanomedicines for cancer immunotherapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081589"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Asma, S.T., Acaroz, U., Imre, K., Morar, A., Shah, S.R.A., Hussain, Z.S., Arslan-Acaroz, D., Demirbas, H., Hajrulai-Musliu, Z., and Istanbullugil, F.R. (2022). Natural products\/bioactive compounds as a source of anticancer drugs. Cancers, 14.","DOI":"10.3390\/cancers14246203"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Odeniran, P.O., Madlala, P., Mkhwanazi, N.P., and Soliman, M.E.S. (2024). Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis. Cancers, 16.","DOI":"10.3390\/cancers16223802"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Feng, L., Sun, J., Shi, Y., Wang, G., and Wang, T. (2020). Predicting suitable habitats of Camptotheca acuminata considering both climatic and soil variables. Forests, 11.","DOI":"10.3390\/f11080891"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Strzelecka, K., Piotrowska, U., Sobczak, M., and Oledzka, E. (2023). The advancement of biodegradable polyesters as delivery systems for camptothecin and its analogues\u2014A status report. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021053"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.2174\/1871520622666220501170405","article-title":"Total synthesis, mechanism of action, and antitumor efficacy of camptothecin and some of its analogues","volume":"22","author":"Bacherikov","year":"2022","journal-title":"Anticancer. Agents Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e70110","DOI":"10.1002\/ctm2.70110","article-title":"Rescuing and utilizing anticancer Nothapodytes species: Integrated studies from plant resources to natural medicines","volume":"14","author":"Peng","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115270","DOI":"10.1016\/j.indcrop.2022.115270","article-title":"Research progress on the biosynthesis and metabolic engineering of the anti-cancer drug camptothecin in Camptotheca acuminata","volume":"186","author":"Fan","year":"2022","journal-title":"Ind. Crops Prod."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12257-025-00187-w","article-title":"Enhancing camptothecin yields: Innovative approaches for sustainable production of anticancer drugs","volume":"30","author":"Jadhav","year":"2025","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s42004-021-00602-2","article-title":"Discovering and harnessing oxidative enzymes for chemoenzymatic synthesis and diversification of anticancer camptothecin analogues","volume":"4","author":"Nguyen","year":"2021","journal-title":"Commun. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Banadka, A., Narasimha, S.W., Dandin, V.S., Naik, P.M., Vennapusa, A.R., Melmaiee, K., Vemanna, R.S., Al-Khayri, J.M., Thiruvengadam, M., and Nagella, P. (2024). Biotechnological approaches for the production of camptothecin. Appl. Microbiol. Biotechnol., 108.","DOI":"10.1007\/s00253-024-13187-2"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141271","DOI":"10.1016\/j.molstruc.2024.141271","article-title":"Synthesis and biological evaluation of new Camptothecin-like compounds as anticancer agents","volume":"1328","author":"Madkour","year":"2025","journal-title":"J. Mol. Struct."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Ruiz, V., Cores, \u00c1., Mart\u00edn-C\u00e1mara, O., Orellana, K., Cervera-Carrasc\u00f3n, V., Michalska, P., Olives, A.I., Le\u00f3n, R., Mart\u00edn, M.A., and Men\u00e9ndez, J.C. (2021). Enhanced stability and bioactivity of natural anticancer topoisomerase I inhibitors through cyclodextrin complexation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101609"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Swamy, M.K., Purushotham, B., and Sinniah, U.R. (2021). Camptothecin: Occurrence, chemistry and mode of action. Bioactive Natural Products for Pharmaceutical Applications, Springer.","DOI":"10.1007\/978-3-030-54027-2_9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112528","DOI":"10.1016\/j.ejmech.2020.112528","article-title":"F10, a new camptothecin derivative, was identified as a new orally\u2013bioavailable, potent antitumor agent","volume":"202","author":"Fan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.xphs.2016.01.026","article-title":"Calculated Log D Is Inversely Correlated with Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts","volume":"105","author":"Nanavati","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-444-63963-9.00002-6","article-title":"The development of pharmaceutical oral solid dosage forms","volume":"Volume 41","author":"Shaikh","year":"2018","journal-title":"Computer Aided Chemical Engineering"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2016.12.023","article-title":"Safe approaches for camptothecin delivery: Structural analogues and nanomedicines","volume":"247","author":"Botella","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.13005\/bpj\/2396","article-title":"The DNA-topoisomerase inhibitors in cancer therapy","volume":"15","author":"Mastrangelo","year":"2022","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103850","DOI":"10.1016\/j.jddst.2022.103850","article-title":"QbD-based and Box-Behnken design assisted oral delivery of stable lactone (active) form of topotecan as PLGA nanoformulation: Cytotoxicity, pharmacokinetic, in vitro, and ex vivo gut permeation studies","volume":"77","author":"Khuroo","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1021\/mp4004018","article-title":"Pharmacokinetics and treatment efficacy of camptothecin nanocrystals on lung metastasis","volume":"11","author":"Zhang","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Almeida, A., Fernandes, E., Sarmento, B., and L\u00facio, M. (2021). A biophysical insight of camptothecin biodistribution: Towards a molecular understanding of its pharmacokinetic issues. Pharmaceutics, 13.","DOI":"10.20944\/preprints202105.0480.v1"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yu, L., Hua, Z., Luo, X., Zhao, T., and Liu, Y. (2022). Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs. Biochim. Biophys. Acta Rev. Cancer, 1877.","DOI":"10.1016\/j.bbcan.2021.188655"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ahmed, H., Bergmann, F., and Zeitlinger, M. (2022). Protein binding in translational antimicrobial development\u2014Focus on interspecies differences. Antibiotics, 11.","DOI":"10.3390\/antibiotics11070923"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104034","DOI":"10.1016\/j.jddst.2022.104034","article-title":"Camptothecin loaded nano-delivery systems in the cancer therapeutic domains: A critical examination of the literature","volume":"79","author":"Alshammari","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100447","DOI":"10.1016\/j.prmcm.2024.100447","article-title":"Unlocking therapeutic precision: Camptotheca acuminata, a traditional Chinese herb tailored for phytonano-cancer theranostics","volume":"11","author":"Adak","year":"2024","journal-title":"Pharmacol. Res. Mod. Chin. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s10311-020-01022-9","article-title":"Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: A review","volume":"18","author":"Behera","year":"2020","journal-title":"Environ. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1021\/acs.jmedchem.3c02115","article-title":"Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1039\/C9NA00752K","article-title":"Understanding the driving forces of camptothecin interactions on the surface of nanocomposites based on graphene oxide decorated with silica nanoparticles","volume":"2","author":"Fonseca","year":"2020","journal-title":"Nanoscale Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-024-02527-x","article-title":"Camptothecin and its derivatives: Advancements, mechanisms and clinical potential in cancer therapy","volume":"41","author":"Kamle","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yakkala, P.A., Penumallu, N.R., Shafi, S., and Kamal, A. (2023). Prospects of topoisomerase inhibitors as promising anti-cancer agents. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101456"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117804","DOI":"10.1016\/j.molliq.2021.117804","article-title":"Theoretical analysis of lactone and carboxylate forms of camptothecin in aqueous solution: Electronic states, absorption spectra, and hydration","volume":"344","author":"Kostjukov","year":"2021","journal-title":"J. Mol. Liq."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"El-Sayed, A.S.A., Hassan, W.H.B., Sweilam, S.H., Alqarni, M.H.S., El Sayed, Z.I., Abdel-Aal, M.M., Abdelsalam, E., and Abdelaziz, S. (2022). Production, bioprocessing, and antiproliferative activity of camptothecin from Penicillium chrysogenum, a marine sponge endosymbiont, as a metabolically stable camptothecin producer. Molecules, 27.","DOI":"10.3390\/molecules27093033"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"114304","DOI":"10.1016\/j.ejmech.2022.114304","article-title":"Topoisomerase I inhibitors: Challenges, progress and the road ahead","volume":"236","author":"Talukdar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Shen, G., Li, S., Zhu, Y., Xu, Z., Liu, X., Lv, C., Xing, Z., Cui, L., and Li, W. (2025). Recent progress in topoisomerase inhibitors as anticancer agents: Research and design strategies for Topo I and II inhibitors via structural optimization. Bioorg. Chem., 165.","DOI":"10.1016\/j.bioorg.2025.109040"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tesauro, C., Simonsen, A.K., Bech Andersen, M., Wandsoe Petersen, K., Laust Kristoffersen, E., and Algreen, L. (2019). Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: A comparative study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6371-0"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Patil, M.A., Sarkate, A.P., Nirmal, N.P., and Sakhale, B.K. (2023). Alkaloids as potential anticancer agents. Recent Front. Phytochem., 203\u2013224.","DOI":"10.1016\/B978-0-443-19143-5.00034-7"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mustafa, M., Ahmad, R., Tantry, I.Q., Ahmad, W., Siddiqui, S., Alam, M., Abbas, K., Moinuddin Hassan, M.I., Habib, S., and Islam, S. (2024). Apoptosis: Una descripci\u00f3n general completa de las v\u00edas de se\u00f1alizaci\u00f3n, los cambios morfol\u00f3gicos y la importancia fisiol\u00f3gica y las implicaciones terap\u00e9uticas. Cells, 13.","DOI":"10.3390\/cells13221838"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/s41467-019-09566-3","article-title":"Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s12276-021-00590-2","article-title":"The p53-caspase-2 axis in the cell cycle and DNA damage response","volume":"53","author":"Lim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/BCJ20210854","article-title":"The concept of intrinsic versus extrinsic apoptosis","volume":"479","author":"Lossi","year":"2022","journal-title":"Biochem. J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Jentsch, M., Snyder, P., Sheng, C., Cristiano, E., and Loewer, A. (2020). P53 dynamics in single cells are temperature-sensitive. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-58267-1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/cdd.2017.170","article-title":"Anti-apoptotic BCL-2 family members in development","volume":"25","author":"Opferman","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/s41467-021-22655-6","article-title":"Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Roufayel, R., Younes, K., Al-Sabi, A., and Murshid, N. (2022). BH3-only proteins Noxa and Puma are key regulators of induced apoptosis. Life, 12.","DOI":"10.3390\/life12020256"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hohorst, L., Ros, U., and Garcia-Saez, A.J. (2025). Mitochondrial dynamics and pore formation in regulated cell death pathways. Trends Biochem. Sci., 1\u201314.","DOI":"10.1016\/j.tibs.2025.09.001"},{"key":"ref_53","first-page":"1119","article-title":"Caspase recruitment domains for protein interactions in cellular signaling (Review)","volume":"43","author":"Park","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vigneswara, V., and Ahmed, Z. (2020). The role of caspase-2 in regulating cell fate. Cells, 9.","DOI":"10.3390\/cells9051259"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s12276-025-01470-9","article-title":"Caspases as master regulators of programmed cell death: Apoptosis, pyroptosis and beyond","volume":"57","author":"Dho","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding apoptosis and apoptotic pathways: Targeted cancer therapies","volume":"9","author":"Jan","year":"2019","journal-title":"Adv. Pharm. Bull."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Eskandari, E., and Eaves, C.J. (2022). Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J. Cell Biol., 221.","DOI":"10.1083\/jcb.202201159"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41420-020-0256-5","article-title":"The nuclear envelope: Target and mediator of the apoptotic process","volume":"6","author":"Lindenboim","year":"2020","journal-title":"Cell Death Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41420-023-01680-y","article-title":"The involvement of caspases in the process of nuclear removal during lens fiber cell differentiation","volume":"9","author":"Gheyas","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/2211-5463.13572","article-title":"Nuclear endonuclease G regulates cell proliferation in ovarian cancer","volume":"13","author":"Choi","year":"2023","journal-title":"FEBS Open Bio."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Schoeniger, A., Wolf, P., and Edlich, F. (2022). How do hexokinases inhibit receptor-mediated apoptosis?. Biology, 11.","DOI":"10.3390\/biology11030412"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Melloul, O., Zabit, S., Lichtenstein, M., Duran, D., Grunewald, M., and Lorberboum-Galski, H. (2025). Targeted and caspase-independent apoptosis induction with novel chimeric proteins for the treatment of solid cancers. Cancers, 17.","DOI":"10.3390\/cancers17071179"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41419-022-04688-x","article-title":"Therapeutic approaches targeting CD95L\/CD95 signaling in cancer and autoimmune diseases","volume":"13","author":"Risso","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Pfeffer, C.M., and Singh, A.T.K. (2018). Apoptosis: A target for cancer therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020448"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_66","first-page":"124","article-title":"Adapter protein\u2014FADD bridges the apoptosis","volume":"6","author":"Marikar","year":"2023","journal-title":"Int. J. Med. Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Guerrache, A., and Micheau, O. (2024). TNF-related apoptosis-inducing ligand: Non-apoptotic signalling. Cells, 13.","DOI":"10.3390\/cells13060521"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.immuni.2019.05.020","article-title":"Caspases in cell death, inflammation, and disease","volume":"50","author":"Lamkanfi","year":"2019","journal-title":"Immunity"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.4014\/jmb.2206.06003","article-title":"DED interaction of FADD and caspase-8 in the induction of apoptotic cell death","volume":"32","author":"Park","year":"2022","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2093615","DOI":"10.1155\/japr\/2093615","article-title":"Apoptosis: A key process that Trypanosoma cruzi modulates as a strategy to perpetuate infection","volume":"2025","year":"2025","journal-title":"J. Parasitol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Pathak, C., Ansari, A., Kumar, A., and Ranjan, K. (2025). Molecular perspective of proteases in modeling of cell death signaling. Preprints, 2025010084.","DOI":"10.20944\/preprints202501.0084.v1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.molcel.2016.01.009","article-title":"Structural basis and functional role of intramembrane trimerization of the Fas\/CD95 death receptor","volume":"61","author":"Fu","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Zhang, W., Zhu, C., Liao, Y., Zhou, M., Xu, W., and Zou, Z. (2024). Caspase-8 in inflammatory diseases: A potential therapeutic target. Cell Mol. Biol. Lett., 29.","DOI":"10.1186\/s11658-024-00646-x"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41421-025-00791-3","article-title":"Caspases: Structural and molecular mechanisms and functions in cell death, innate immunity, and disease","volume":"11","author":"Nadendla","year":"2025","journal-title":"Cell Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.immuni.2020.04.010","article-title":"Caspase-8-dependent inflammatory responses are controlled by its adaptor, FADD, and necroptosis","volume":"52","author":"Tummers","year":"2020","journal-title":"Immunity"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12964-023-01247-5","article-title":"Regulation of anoikis by extrinsic death receptor pathways","volume":"21","author":"Han","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/j.csbj.2020.10.008","article-title":"Functional roles in cell signaling of adaptor protein TRADD from a structural perspective","volume":"18","author":"Li","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wy\u017cewski, Z., Gregorczyk-Zboroch, K.P., Mielcarska, M.B., \u015awitlik, W., and Niedzielska, A. (2025). Bid protein: A participant in the apoptotic network with roles in viral infections. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062385"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Makinwa, Y., Luo, Y., Musich, P.R., and Zou, Y. (2024). Canonical and non-canonical functions of BH3-only protein in apoptosis, oncogenesis, cancer therapeutics, and aging. Cancers, 16.","DOI":"10.3390\/cancers16122199"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e108690","DOI":"10.15252\/embj.2021108690","article-title":"The BCL-2 family protein tBID acts as a BAX-like apoptosis effector","volume":"41","author":"Hohorst","year":"2022","journal-title":"EMBO J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41419-021-04240-3","article-title":"A long way to go: Caspase inhibitors in clinical use","volume":"12","author":"Dhani","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Mandal, R., Compte Barr\u00f3n, J., Kostova, I., Becker, S., and Strebhardt, K. (2020). Caspase-8: The double-edged sword. Biochim. Biophys. Acta Rev. Cancer, 1873.","DOI":"10.1016\/j.bbcan.2020.188357"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/encyclopedia2040111","article-title":"Apoptosis regulators Bcl-2 and caspase-3","volume":"2","author":"Hussar","year":"2022","journal-title":"Encyclopedia"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wang, Z. (2021). Regulation of cell cycle progression by growth factor-induced cell signaling. Cells, 10.","DOI":"10.3390\/cells10123327"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/JLB.3MR0420-305R","article-title":"Multiple roles of caspase-8 in cell death, inflammation, and innate immunity","volume":"109","author":"Orning","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41418-024-01320-7","article-title":"The caspase-activated DNase drives inflammation and contributes to defense against viral infection","volume":"31","author":"Moeed","year":"2024","journal-title":"Cell Death Differ."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10495-022-01735-y","article-title":"Programmed Cell Death Detection Methods: A Systematic Review and a Categorical Comparison","volume":"27","author":"Kari","year":"2022","journal-title":"Apoptosis"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41419-025-07964-8","article-title":"CAD hijacks STING to impair antitumor immunity and radiotherapy efficacy of colorectal cancer","volume":"16","author":"Cai","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ahmad Bhat, I., Maqsood Bhat, A., and Tasduq Abdullah, S. (2025). Apoptosis\u2014Mechanisms, Regulation in Pathology, and Therapeutic potential. Biochemistry, IntechOpen.","DOI":"10.5772\/intechopen.1008890"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature20141","article-title":"Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation","volume":"539","author":"Han","year":"2016","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"115710","DOI":"10.1016\/j.ejmech.2023.115710","article-title":"The recent developments of camptothecin and its derivatives as potential anti-tumor agents","volume":"260","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21342","article-title":"Perspectives on biologically active camptothecin derivatives","volume":"35","author":"Liu","year":"2015","journal-title":"Med. Res. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"116872","DOI":"10.1016\/j.ejmech.2024.116872","article-title":"Drug combinations of camptothecin derivatives promote the antitumor properties","volume":"279","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Dai, Y., Qian, M., and Li, Y. (2023). Structural Modification Endows Small-Molecular SN38 Derivatives with Multifaceted Functions. Molecules, 28.","DOI":"10.3390\/molecules28134931"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/10717544.2014.911394","article-title":"Hydroxyethyl starch\u201310-hydroxycamptothecin conjugate: Synthesis, pharmacokinetics, cytotoxicity and pharmacodynamic investigation","volume":"23","author":"Li","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Avenda\u00f1o, C., and Men\u00e9ndez, J.C. (2023). DNA intercalation and topoisomerase inhibition. Medicinal Chemistry of Anticancer Drugs, Elsevier. [2nd ed.].","DOI":"10.1016\/B978-0-12-818549-0.00010-8"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Pullaiah, T., and Raveendran, V. (2020). Camptothecin: Chemistry, biosynthesis, analogs, and chemical synthesis. Camptothecin and Camptothecin Producing Plants: Botany, Chemistry, Anticancer Activity and Biotechnology, Academic Press.","DOI":"10.1016\/B978-0-12-820499-3.00002-1"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.compbiomed.2012.06.012","article-title":"CoMFA QSAR models of camptothecin analogues based on the distinctive SAR features of combined ABC, CD and E ring substitutions","volume":"42","author":"Virupaksha","year":"2012","journal-title":"Comput. Biol. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21037\/atm.2019.12.138","article-title":"A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell","volume":"8","author":"Liu","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, M., Zhu, L.-Z., Yang, C.-J., Yan, J.-X., Wang, Z.-P., Bai, Y.-P., Peng, L.-Z., Luo, H.-B., Zhang, Z.-J., and Li, L. (2023). Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I. Bioorg. Chem., 139.","DOI":"10.1016\/j.bioorg.2023.106652"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2012.07.050","article-title":"Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents","volume":"56","author":"Zhu","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bmcl.2018.11.049","article-title":"Synthesis and antitumor activity of biotinylated camptothecin derivatives as potent cytotoxic agents","volume":"29","author":"Zi","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Dai, X., Wu, G., Zhang, Y., Zhang, X., Yin, R., Qi, X., Li, J., and Jiang, T. (2020). Design, synthesis, and in vitro\/in vivo anti-cancer activities of novel (20S)-10,11-methylenedioxy-camptothecin heterocyclic derivatives. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228495"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000443404","article-title":"Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents","volume":"25","author":"Cragg","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"ref_105","unstructured":"Levin, S.A. (2013). Plant sources of drugs and chemicals. Encyclopedia of Biodiversity, Elsevier. [2nd ed.]."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/08982104.2020.1801725","article-title":"Engineered liposomes bearing camptothecin analogue for tumour targeting: In vitro and ex-vivo studies","volume":"31","author":"Saraf","year":"2020","journal-title":"J. Liposome Res."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Lichota, A., and Gwozdzinski, K. (2018). Anticancer activity of natural compounds from plant and marine environment. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113533"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/med.21466","article-title":"Biologically active quinoline and quinazoline alkaloids, part I","volume":"38","author":"Shang","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Di Nunzio, M.R., and Douhal, A. (2023). Robust inclusion complex of topotecan comprised within a rhodamine-labeled \u03b2-cyclodextrin: Competing proton and energy transfer processes. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061620"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1158\/1535-7163.MCT-14-0475","article-title":"Tissue penetration and activity of camptothecins in solid tumor xenografts","volume":"13","author":"Kyle","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Jeong, S.H., Jang, J.H., and Lee, Y.B. (2020). Pharmacokinetic comparison of three different administration routes for topotecan hydrochloride in rats. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090231"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Varsha, K., Sharma, A., Kaur, A., Madan, J., Pandey, R.S., Jain, U.K., and Chandra, R. (2017). Natural plant-derived anticancer drugs nanotherapeutics: A review on preclinical to clinical success. Nanostructures for Cancer Therapy, Elsevier.","DOI":"10.1016\/B978-0-323-46144-3.00028-3"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1573394717666210202103502","article-title":"Adverse effects and safety of etirinotecan pegol, a novel topoisomerase inhibitor, in cancer treatment: A systematic review","volume":"17","author":"Samareh","year":"2021","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bcp.12606","article-title":"Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumors and impaired renal function","volume":"80","author":"Devriese","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Lambrecht, L., Arnold, P., Behr, J., Mertsch, P., Tufman, A., and Kauffmann-Guerrero, D. (2024). Topotecan in a real-world small-cell lung cancer cohort: Prognostic biomarkers improve selection of patients for second-line treatment. Diagnostics, 14.","DOI":"10.3390\/diagnostics14141572"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e3180986262","article-title":"Current status of second-line treatment and novel therapies for small cell lung cancer","volume":"2","author":"Tiseo","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.pan.2022.06.004","article-title":"Nal-IRI\/5-FU\/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study","volume":"22","author":"Tezuka","year":"2022","journal-title":"Pancreatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clon.2023.02.008","article-title":"Comparative effectiveness of FOLFIRINOX versus gemcitabine and nab-paclitaxel in initially unresectable locally advanced pancreatic cancer: A population-based study to assess subsequent surgical resection and overall survival","volume":"35","author":"Dai","year":"2023","journal-title":"Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"104398","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/IJN.S435407","article-title":"Research progress of SN38 drug delivery system in cancer treatment","volume":"19","author":"Qi","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of irinotecan treatment: A review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","volume":"57","author":"Goey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan: A key chemotherapeutic agent for metastatic colorectal cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/2212697X08666211206102503","article-title":"Chemoresistance mechanisms in colon cancer: Focus on conventional chemotherapy","volume":"8","year":"2021","journal-title":"Clin. Cancer Drugs."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Yang, X., Chen, J., Wang, Y., Wu, Y., and Zhang, J. (2025). Managing irinotecan-induced diarrhea: A comprehensive review of therapeutic interventions in cancer treatment. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030359"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","article-title":"FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance","volume":"14","author":"Westover","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT Trial Investigators. RESILIENT Part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.2025.43.16_suppl.1029","article-title":"IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients with HER2-positive breast cancer and other solid tumors: Updates from a phase 1 study","volume":"43","author":"Lemech","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1007\/s00432-023-04647-9","article-title":"Pazopanib with topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: Results of a multicentre, open-label phase I\/II study (TOPAZ)","volume":"149","author":"Chekerov","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Das, S., and Samaddar, S. (2025). Recent advances in the clinical translation of small-cell lung cancer therapeutics. Cancers, 17.","DOI":"10.3390\/cancers17020255"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Xu, J., Wen, J., Ji, X., Chen, J., Yang, M., Hong, M., and Deng, D. (2025). Preclinical development of a high affinity anti-exatecan monoclonal antibody and application in bioanalysis of antibody-exatecan conjugates. J. Pharm. Biomed. Anal., 262.","DOI":"10.1016\/j.jpba.2025.116843"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Pillai, G. (2019). Nanotechnology toward treating cancer: A comprehensive review. Applications of Targeted Nano Drugs and Delivery Systems, Elsevier.","DOI":"10.1016\/B978-0-12-814029-1.00009-0"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Olender, D., \u017bwawiak, J., and Zaprutko, L. (2018). Multidirectional efficacy of biologically active nitro compounds included in medicines. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020054"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41416-020-01055-5","article-title":"A randomized phase 2b study comparing the efficacy and safety of belotecan versus topotecan as monotherapy for sensitive-relapsed small-cell lung cancer","volume":"124","author":"Kang","year":"2021","journal-title":"Br. J. Cancer."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000535491","article-title":"Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates","volume":"47","author":"Wang","year":"2024","journal-title":"Oncol. Res. Treat."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Gong, J., Zhang, W., and Balthasar, J.P. (2025). Camptothecin-based anti-cancer therapies and strategies to improve their therapeutic index. Cancers, 17.","DOI":"10.3390\/cancers17061032"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Tonon, G., Rizzolio, F., Visentin, F., and Scattolin, T. (2024). Antibody drug conjugates for cancer therapy: From metallodrugs to nature-inspired payloads. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168651"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Han, S., Lim, K.S., Blackburn, B.J., Yun, J., Putnam, C.W., Bull, D.A., and Won, Y.W. (2022). The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081707"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Khan, S., Jandrajupalli, S.B., Bushara, N.Z.A., Raja, R.D.P., Mirza, S., Sharma, K., Verma, R., Kumar, A., and Lohani, M. (2024). Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine. Cells, 13.","DOI":"10.20944\/preprints202411.0312.v1"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Indini, A., Rijavec, E., and Grossi, F. (2021). Trastuzumab deruxtecan: Changing the destiny of HER2 expressing solid tumors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094774"},{"key":"ref_140","first-page":"124","article-title":"Apoptosis y c\u00e1ncer","volume":"9","year":"2020","journal-title":"Prensa. Med. Argent."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2174\/0929867311320120006","article-title":"Camptothecin resistance in cancer: Insights into the molecular mechanisms of a DNA-damaging drug","volume":"20","author":"Beretta","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Stasiak, P., Sopel, J., P\u0142\u00f3ciennik, A., Musielak, O., Lipowicz, J.M., Raw\u0142uszko-Wieczorek, A.A., Sterzy\u0144ska, K., Korbecki, J., and Januchowski, R. (2025). Elacridar inhibits BCRP protein activity in 2D and 3D cell culture models of ovarian cancer and re-sensitizes cells to cytotoxic drugs. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125800"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Godbey, W.T. (2014). Cellular transport. An Introduction to Biotechnology, Academic Press. [1st ed.].","DOI":"10.1016\/B978-1-907568-28-2.00003-4"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_145","first-page":"946","article-title":"Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: A review","volume":"4","author":"Ozawa","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/138920021602150713114921","article-title":"Interaction of isoflavones with the drug transporter BCRP\/ABCG2","volume":"16","author":"Bircsak","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Kundu, M.K., Dey, A., and Rahman, M.H. (2022). Multidrug resistance in cancer cells: Focus on a possible strategy plan to address colon carcinoma cells. Life, 12.","DOI":"10.3390\/life12060811"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Bahar, E., Kim, J.Y., Kim, H.S., and Yoon, H. (2020). Establishment of acquired cisplatin resistance in ovarian cancer cell lines characterized by enriched metastatic properties with increased Twist expression. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207613"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/1535-7163.MCT-15-0789","article-title":"Novel ABCG2 antagonists reverse topotecan-mediated chemotherapeutic resistance in ovarian carcinoma xenografts","volume":"15","author":"Ricci","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"43733","DOI":"10.18632\/oncotarget.16376","article-title":"Camptothecin resistance is determined by topoisomerase I degradation regulation through the ubiquitin proteasome pathway","volume":"8","author":"Ando","year":"2017","journal-title":"Oncotarget"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Kumar, S., and Sherman, M.Y. (2023). Resistance to TOP-1 inhibitors: Good old drugs still can surprise us. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087233"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Saurav, S., Karfa, S., Vu, T., Liu, Z., Datta, A., Manne, U., Samuel, T., and Datta, P.K. (2024). Overcoming irinotecan resistance by targeting its downstream signaling pathways in colon cancer. Cancers, 16.","DOI":"10.3390\/cancers16203491"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Sharma, N.K., Bahot, A., Sekar, G., Bansode, M., Khunteta, K., Sonar, P.V., Hebale, A., Salokhe, V., and Sinha, B.K. (2024). Understanding Cancer\u2019s Defense against Topoisomerase-Active Drugs: A Comprehensive Review. Cancers, 16.","DOI":"10.3390\/cancers16040680"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Jado, J.C., Dow, M., Carolino, K., Klie, A., Fonseca, G.J., Ideker, T., Carter, H., and Winzeler, E.A. (2024). In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-63943-7"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbcan.2012.09.002","article-title":"Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors","volume":"1835","author":"Tomicic","year":"2013","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Fern\u00e1ndez, L., Mill\u00e1n-Garc\u00eda, A., Merino, G., and Blanco-Paniagua, E. (2025). ABCG2 transporter: From structure to function\u2014Current insights and open questions. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136119"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"DNA repair targeted therapy: The past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.jmb.2016.11.006","article-title":"Traveling rocky roads: The consequences of transcription-blocking DNA lesions on RNA polymerase II","volume":"429","author":"Steurer","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: Mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA topoisomerase II and other cancer-related targets","volume":"63","author":"Skok","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Yamashita, M., Tsukamoto, M., Imai, R., Muramatsu, H., and Nakagawa, H. (2025). rs2231142 (421 C>A, Q141K) Is More Functionally Influential than rs2231137 (34 G>A, V12M) on Anticancer Drug Resistance Mediated by the ABCG2 Haplotype In Vitro. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157428"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Cravo, D.L.d.M., Pimentel, P.A.B., Garcia, A.P.V., Junqueira, A.L.d.M., Soares, F.S., Giuliano, A., Almendros, A., and Horta, R.d.S. (2025). Comparative Analysis of Chemotherapy Resistance Mechanisms in Humans and Companion Animals. Vet. Sci., 12.","DOI":"10.3390\/vetsci12080747"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Bianchi, N., Ancona, P., and Aguiari, G. (2025). Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell Carcinoma. Cancers, 17.","DOI":"10.3390\/cancers17101613"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-10-64","article-title":"New topoisomerase I mutations are associated with resistance to camptothecin","volume":"10","author":"Gongora","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3892\/or.2013.2594","article-title":"Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines","volume":"30","author":"Arakawa","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s00432-022-04140-9","article-title":"Nurses\u2019 knowledge of chemotherapy-induced neutropenia and its management: A cross-sectional survey","volume":"149","author":"Ballad","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_168","first-page":"883","article-title":"Gastrointestinal symptoms in the journey of pancreatic cancer patients","volume":"19","author":"Pisani","year":"2025","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Karlovi\u0107, D., Klarica, L., Kr\u0161ul, D., Simi\u010di\u0107, N., Jerkovi\u0107, A., Miloti\u0107, M., and Zeli\u0107, M. (2025). Fecal Incontinence: How to Approach and Treat?, IntechOpen.","DOI":"10.5772\/intechopen.1009657"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7150\/jca.99421","article-title":"Important role of gut microbiota in chemotherapy-induced diarrhea and therapeutics","volume":"16","author":"Jiang","year":"2025","journal-title":"J. Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10735-025-10367-w","article-title":"Restore intestinal steady-state: New advances in the clinical management of chemotherapy-associated diarrhea and constipation","volume":"56","author":"Chen","year":"2025","journal-title":"J. Mol. Histol."},{"key":"ref_172","first-page":"101781","article-title":"Successful management of severe refractory haemorrhagic cystitis secondary to cyclophosphamide and BK virus with cystotomy and alum infusion","volume":"39","author":"Mak","year":"2021","journal-title":"Urol. Case Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jemermed.2016.04.010","article-title":"Red blood cell transfusion in the emergency department","volume":"51","author":"Long","year":"2016","journal-title":"J. Emerg. Med."},{"key":"ref_174","unstructured":"American Cancer Society (2024, August 28). N\u00e1useas y V\u00f3mitos por Quimioterapia. Atlanta: American Cancer Society. Available online: https:\/\/www.cancer.org\/es\/cancer\/como-sobrellevar-el-cancer\/efectos-secundarios\/problemas-alimentarios\/nauseas-y-vomito\/quimio-nauseas-vomitos.html."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Fischer, O.W., Justesen, T.F., G\u00f6genur, D.S., Madsen, M.T., Mortensen, M.B., G\u00f6genur, I., and Orhan, A. (2025). Long-term oncological outcomes of granulocyte colony-stimulating factor (G-CSF) treatment in gastrointestinal cancers: A systematic review and meta-analysis. Cancers, 17.","DOI":"10.3390\/cancers17081313"},{"key":"ref_176","first-page":"128","article-title":"Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis","volume":"29","author":"Aslam","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Ghanbari-Movahed, M., Kaceli, T., Mondal, A., Hosein Farzaei, M., and Bishayee, A. (2021). Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050480"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s44301-025-00008-2","article-title":"Nanotechnology in medicine: A double-edged sword for health outcomes","volume":"1","author":"Fortune","year":"2025","journal-title":"Health Nanotechnol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Malik, S., Muhammad, K., and Waheed, Y. (2023). Emerging Applications of Nanotechnology in Healthcare and Medicine. Molecules, 28.","DOI":"10.3390\/molecules28186624"},{"key":"ref_180","first-page":"1","article-title":"Gobernanza de la nanomedicina: Una revisi\u00f3n sistem\u00e1tica","volume":"15","year":"2021","journal-title":"Mundo Nano."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: Why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Delgado-Pujol, E.J., Mart\u00ednez, G., Casado-Jurado, D., V\u00e1zquez, J., Le\u00f3n-Barberena, J., Rodr\u00edguez-Lucena, D., Torres, Y., Alcudia, A., and Begines, B. (2025). Hydrogels and nanogels: Pioneering the future of advanced drug delivery systems. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17020215"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Eltaib, L. (2025). Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers, 17.","DOI":"10.3390\/polym17070833"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Kazi, R.N.A., Hasani, I.W., Khafaga, D.S.R., Kabba, S., Farhan, M., Aatif, M., Muteeb, G., and Fahim, Y.A. (2025). Nanomedicine: The effective role of nanomaterials in healthcare from diagnosis to therapy. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080987"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Deng, Z., Al Siraj, A., Lowry, I., Ruan, E., Patel, R., Gao, W., Kalin, T.V., and Kalinichenko, V.V. (2025). Nanoparticle-based delivery systems for synergistic therapy in lung cancers. Bioengineering, 12.","DOI":"10.3390\/bioengineering12090968"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.partic.2021.05.009","article-title":"Nanoemulsions for drug delivery","volume":"64","author":"Russell","year":"2022","journal-title":"Particuology"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Najahi-Missaoui, W., Arnold, R.D., and Cummings, B.S. (2021). Safe nanoparticles: Are we there yet?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010385"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"101174","DOI":"10.1016\/j.jddst.2019.101174","article-title":"Metal nanoparticles synthesis: An overview on methods of preparation, advantages and disadvantages, and applications","volume":"53","author":"Jamkhande","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"106556","DOI":"10.1016\/j.ejps.2023.106556","article-title":"Lipid based formulations as supersaturating oral delivery systems: From current to future industrial applications","volume":"189","author":"Holm","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s10311-021-01216-9","article-title":"Nanoemulsions for health, food, and cosmetics: A review","volume":"19","author":"Ashaolu","year":"2021","journal-title":"Environ. Chem. Lett."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3746\/pnf.2019.24.3.225","article-title":"Techniques for formulation of nanoemulsion drug delivery system: A review","volume":"24","author":"Kumar","year":"2019","journal-title":"Prev. Nutr. Food Sci."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Gupta, A. (2020). Nanoemulsions. Nanoparticles for Biomedical Applications, Elsevier.","DOI":"10.1016\/B978-0-12-816662-8.00021-7"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"101870","DOI":"10.1016\/j.jsps.2023.101870","article-title":"Exploring lipids for their potential to improve bioavailability of lipophilic drug candidates: A review","volume":"31","author":"Preeti","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.msec.2019.04.066","article-title":"Silver nanoparticles as plasmon-resonant enhancers for eumelanin\u2019s photoacoustic signal in a self-structured hybrid nanoprobe","volume":"102","author":"Silvestri","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"260","DOI":"10.15446\/rcciquifa.v48n2.82696","article-title":"Sistemas de entrega de f\u00e1rmacos autoemulsificables: Una plataforma de desarrollo alternativa para la industria farmac\u00e9utica colombiana","volume":"48","author":"Cueto","year":"2019","journal-title":"Rev. Colomb. Cienc. Qu\u00edm. Farm."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Mohite, P., Singh, S., Pawar, A., Sangale, A., and Prajapati, B.G. (2023). Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front. Drug Deliv., 3.","DOI":"10.3389\/fddev.2023.1232012"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Silva, A.C., Moreira, J.N., and Sousa Lobo, J.M. (2023). Current insights on lipid-based nanosystems 2023. Pharmaceuticals, 16.","DOI":"10.3390\/books978-3-0365-9805-5"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2019.08.014","article-title":"Natural product-based nanoformulations for cancer therapy: Opportunities and challenges","volume":"69","author":"Kashyap","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jconrel.2022.07.029","article-title":"Oral delivery of camptothecin-loaded multifunctional chitosan-based micelles is effective in reduce colorectal cancer","volume":"349","author":"Almeida","year":"2022","journal-title":"J. Control Release."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.nano.2018.05.021","article-title":"Lipid based nanocarriers: A translational perspective","volume":"14","author":"Mishra","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejpb.2023.08.009","article-title":"A critical review of the novelties in the development of intravenous nanoemulsions","volume":"191","author":"Czerniel","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Pinel, B., Porras-Alcal\u00e1, C., Ortega-Rodr\u00edguez, A., Sarabia, F., Prados, J., Melguizo, C., and L\u00f3pez-Romero, J.M. (2019). Nanopart\u00edculas basadas en l\u00edpidos: Aplicaci\u00f3n y avances recientes en el tratamiento del c\u00e1ncer. Nanomaterials, 9.","DOI":"10.3390\/nano9040638"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity","volume":"91","author":"Maeda","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","article-title":"Functional ligands for improving anticancer drug therapy: Current status and applications to drug delivery systems","volume":"29","author":"Bajracharya","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Vagena, I.A., Malapani, C., Gatou, M.A., Lagopati, N., and Pavlatou, E.A. (2025). Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives. Appl. Sci., 15.","DOI":"10.3390\/app15063189"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Sanit\u00e0, G., Carrese, B., and Lamberti, A. (2020). Nanoparticle surface functionalization: How to improve biocompatibility and cellular internalization. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.587012"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Padhi, S., and Behera, A. (2021). Advanced drug delivery systems in the treatment of ovarian cancer. Advanced Drug Delivery Systems in the Management of Cancer, Academic Press.","DOI":"10.1016\/B978-0-323-85503-7.00020-1"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Chen, Y., Tang, Y., Li, Y., Rui, Y., and Zhang, P. (2024). Enhancing the efficacy of active pharmaceutical ingredients in medicinal plants through nanoformulations: A promising field. Nanomaterials, 14, Erratum in Nanomaterials 2025, 15, 1442.","DOI":"10.3390\/nano15181442"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Alrushaid, N., Khan, F.A., Al-Suhaimi, E.A., and Elaissari, A. (2023). Nanotechnology in cancer diagnosis and treatment. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15031025"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"124292","DOI":"10.1016\/j.ijpharm.2024.124292","article-title":"Polymeric micelles paving the way: Recent breakthroughs in camptothecin delivery for enhanced chemotherapy","volume":"659","author":"Farhoudi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.2147\/IJN.S378074","article-title":"Nanotechnology: A promising approach for cancer diagnosis, therapeutics and theragnosis","volume":"17","author":"Dessale","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.copbio.2021.12.011","article-title":"Application of nanotechnology in medical diagnosis and imaging","volume":"74","author":"Singh","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1021\/acsabm.2c00002","article-title":"Recent progress in nanostructured smart drug delivery systems for cancer therapy: A review","volume":"5","author":"Khan","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_214","first-page":"e29059","article-title":"The application of nanotechnology and nanomaterials in cancer diagnosis and treatment: A review","volume":"14","author":"Kher","year":"2022","journal-title":"Cureus"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Liu, Z., Zhou, Y., Lu, J., Gong, T., Ib\u00e1\u00f1ez, E., Cifuentes, A., and Lu, W. (2024). Microfluidic Biosensors for Biomarker Detection in Body Fluids: A Key Approach for Early Cancer Diagnosis. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00697-4"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"718-e694","DOI":"10.1093\/oncolo\/oyac100","article-title":"A single-arm phase II study combining NLG207, a nanoparticle camptothecin, with enzalutamide in advanced metastatic castration-resistant prostate cancer post-enzalutamide","volume":"27","author":"Schmidt","year":"2022","journal-title":"Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10549-020-05995-7","article-title":"Phase I study of liposomal irinotecan in patients with metastatic breast cancer: Findings from the expansion phase","volume":"185","author":"Sachdev","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_218","first-page":"100057","article-title":"Innovative irinotecan-loaded nanomicelles will enter Phase I clinical trial in 2021","volume":"1","author":"Li","year":"2020","journal-title":"Transl. Patent"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.nano.2019.02.021","article-title":"Phase I\/II trial of CRLX101 nanocamptothecin with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer","volume":"18","author":"Sanoff","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.2147\/IJN.S488545","article-title":"Nanoemulsions based therapeutic strategies: Enhancing targeted drug delivery against breast cancer cells","volume":"20","author":"Izadiyan","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Amparo, T.R., Almeida, T.C., Sousa, L.R.D., Xavier, V.F., da Silva, G.N., Brand\u00e3o, G.C., and dos Santos, O.D.H. (2025). Nanostructured formulations for a local treatment of cancer: A mini review about challenges and possibilities. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17020205"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Parvin, N., Aslam, M., Joo, S.W., and Mandal, T.K. (2025). Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications. Molecules, 30.","DOI":"10.3390\/molecules30153177"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"103929","DOI":"10.1016\/j.jddst.2022.103929","article-title":"Oral self-emulsifying nanoemulsion systems for enhancing dissolution, bioavailability and anticancer effects of camptothecin","volume":"78","author":"Trivedi","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_224","first-page":"56","article-title":"Nanomedicina desde una perspectiva tecnol\u00f3gica: Revisi\u00f3n de literatura","volume":"8","year":"2020","journal-title":"Rev. Investig. Tecnol. Inf."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1414\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:38:12Z","timestamp":1762234692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":224,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pharmaceutics17111414"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17111414","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}